Showing results (131-140 of 396) with videos related to
Sort By:
Pageof 40
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 23, 2025
Facts and Hopes: Toward the Next Quantum Leap in MelanomaKeith T Flaherty, Andrew E Aplin, Michael A Davies, et al.Journal of the American Academy of Dermatology|August 21, 2016
Ki-67, p53, and p16 expression, and G691S RET polymorphism in desmoplastic melanoma (DM): A clinicopathologic analysis of predictors of outcomeNicholas F Lawrence, Marc R Hammond, Dennie T Frederick, et al.Cancer Chemotherapy and Pharmacology|January 15, 2004
Phase I trial of the antifolate ZD9331 in combination with cisplatin in patients with refractory solid malignanciesJoshua H Bilenker, James P Stevenson, Keith T Flaherty, et al.The Journal of Investigative Dermatology|March 20, 2015
MITF Modulates Therapeutic Resistance through EGFR SignalingZhenyu Ji, Yiyin Erin Chen, Raj Kumar, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 18, 2011
Phase I, dose-escalation trial of the oral cyclin-dependent kinase 4/6 inhibitor PD 0332991, administered using a 21-day schedule in patients with advanced cancerKeith T Flaherty, Patricia M Lorusso, Angela Demichele, et al.Molecular Cancer Therapeutics|June 21, 2023
Targeting Upregulated cIAP2 in SOX10-Deficient Drug Tolerant MelanomaMcKenna Q Glasheen, Signe Caksa, Amelia G Young, et al.Pigment Cell & Melanoma Research|February 1, 2017
MicroRNA-125a promotes resistance to BRAF inhibitors through suppression of the intrinsic apoptotic pathwayLisa Koetz-Ploch, Douglas Hanniford, Igor Dolgalev, et al.Cancer Research|July 18, 2008
Identification of a novel subgroup of melanomas with KIT/cyclin-dependent kinase-4 overexpressionKeiran S M Smalley, Rooha Contractor, Thiennga K Nguyen, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 5, 2005
Phase I trial of combretastatin a-4 phosphate with carboplatinJoshua H Bilenker, Keith T Flaherty, Mark Rosen, et al.Cancer Discovery|December 28, 2014
EPHA2 is a mediator of vemurafenib resistance and a novel therapeutic target in melanomaBenchun Miao, Zhenyu Ji, Li Tan, et al.Pageof 40